Interested in a PhD in medical mycology? Applications are now open for the MycoDTP training programme! 🧫 Deadline for applications: 4th December 2026 Find out more and apply mycodtp.org/

In a randomized trial involving adults who received local antibiotics during surgery for orthopedic infection, a short duration of systemic antibiotics was noninferior to a long duration regarding treatment failure at 12 months. Full SOLARIO trial results: nej.md/4dgrqwY

Chronic aspergillosis sometimes occurs alongside other long-term lung conditions and infections If you are affected by NTM (non-tuberculous Mycobacterium) and/or bronchiectasis, you can find out more with this online event aimed at patients and their families

Our review on COPD and aspergillus interaction just published in @TheLancetInfDis ! We highlight an under-recognised burden and major opportunities for prevention, earlier diagnosis and treatment. pubmed.ncbi.nlm.nih.gov/4261… @MFT_NAC

Congratulations to the @remap_cap investigators for conducting this important clinical trial, which will undoubtedly change clinical practice and treatment guidelines (or at least it should). Free link in first reply. @NEJM

NAC & @mimslearning offer a CPD course about #aspergillosis for GPs, to support them in managing patients with fungal lung conditions 🫁 #respiratory #GPs #pulmonary #respisbest #ABPA #MedEd #CME #NHS

Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients - businesswire.com/news/home/2…

Would you like to do your #PhD in fungal lung infections? NAC accept applications all year round ✴️Personalised approach to antifungal treatment in chronic fungal lung disease✴️ 👉More info at findaphd.com #phdjobs #academicjobs #sciencejobs #Manchester #findaphd

One-month treatment for latent tuberculosis. Why aren't we using it? (Hint: We should.) @NEJM @NEJMClinician voices.nejm.org/doi/full/10.…

UCB therapeutics announces they will trial anti-IL17/IL-13 multispecific antibody therapy in bronchiectasis in 2026 The pipeline of new therapies coming into the bronchiectasis and COPD field is exciting to see and will ultimately be great for patients. ucb.com/newsroom/press-relea…

🆕⚡🟢Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis Higher pyrazinamide and isoniazid exposures and slow NAT2 acetylator status were independently associated with hepatotoxicity. In multivariable analysis, only pyrazinamide exposure was associated with hepatotoxicity. Rifampicin exposure up to 20 mg/kg/day was not associated with hepatotoxicity, supporting its safe use. #IDXposts academic.oup.com/cid/article…

Don't worry if you missed #WorldAspergillosisDay - the recordings are now online: piped.video/@nationalaspergi… Huge thanks to everyone who attended, hope to see you all again next year! #IDtwitter #medtwitter #respiratory #respisbest #NHS @ckosmidis @MycologyRefManc @aspertrust

Today is #WorldAspergillosisDay - you can help by sharing this link with any GPs you know NAC worked with MIMS to produce this CPD course for learning about #aspergillosis to help CPA and #ABPA be diagnosed and treated faster #respiratory #GPs #pulmonary #respisbest

Our new paper in Mycoses: Aspergillus serology predicts relapse in chronic pulmonary aspergillosis (#CPA). End-of-therapy ↑IgG and Aspergillus sensitisation predicted relapse. 👉 Towards personalised follow-up in CPA pubmed.ncbi.nlm.nih.gov/4161… @MFT_NAC @eurconfmedmycol

Only 4 days until #WorldAspergillosisDay - have you registered? 🫁 ➡️ eventbrite.co.uk/e/198070713… Pls retweet! @ckosmidis #respiratory @aspertrust @gaffi_org #ABPA #aspergilloma #idtwitter @EuropeanLung @BTSrespiratory @asthmalunguk @AFWGonline @MycologyRefManc @MRCcmm @MMSNIG

Looking forward to our 2026 World Aspergillosis Day event!

Registration for NAC's #WorldAspergillosisDay meeting is now open! 👉eventbrite.co.uk/e/198070713… 🗓️Tues 3 Feb - Antifungal resistance - CPA risk genes - Adrenal insufficiency - Current aspergillosis clinical trials #idtwitter @aspertrust @MycologyRefManc @ckosmidis @UofMMFIG

🫁 Chronic pulmonary aspergillosis + OPAT Our new JAC-AMR paper describes successful treatment with once-weekly rezafungin in a patient with #CPA, with improved convenience and potential cost savings vs daily echinocandins. academic.oup.com/jacamr/arti… @MFT_NAC @MundipharmaTalk